Open-Label Study of BBO-10203
Phase 1
392
about 4.1 years
18+
19 sites in CA, FL, IN +7
What this study is about
This trial is testing the safety and how well BBO-10203 works in people with advanced solid tumors. It's a first-in-human trial to see if this new drug can be safely used alone or with other cancer treatments.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take BBO-10203
- 2.Take Bevacizumab
- 3.Take FOLFOX
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
bevacizumab, fulvestrant, ribociclib, trastuzumab (Monoclonal antibody; targets HER2 protein on cancer cells)
infusion, injection, oral (Oral Tablet), intravenous
Primary: Determination of maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of BBO-10203 as a single agent, Percentage of patients with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs)
Secondary: Area under the concentration-time curve (AUC, Duration of response (DOR) as assessed by RECIST v1.1., Maximum plasma drug concentration (Cmax), Objective response rate (ORR) as assessed by RECIST v1.1 for patients with measurable disease, Overall survival (OS), Progression-free survival (PFS) as assessed by RECIST v1.1, Time for maximum plasma drug concentration (Tmax)
Oncology